Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Barrier Function and Mucosal Models : Using BPC-157 and KPV-containing preparations to explore epithelial integrity in gastrointestinal and other mucosal tissues
That environment can create a false sense of confidence
Clinical Data from Competitor Agents: Strengths and Limitations of CT-388 in Light of Competitor Data: Strengths: - CT-388 demonstrates a positive safety and tolerability profile with manageable GI-related side effects that are consistent with the incretin class.- CT-388 has shown statistically significant weight loss across cohorts in its Phase 1/2 trial, with the highest dose cohort (Cohort 8) averaging an 8.4% weight loss at four weeks.- The prolonged half-life of CT-388 suggests the potential for once-weekly dosing, which could bolster adherence compared to therapies requiring more frequent administration.- Weight loss with CT-388 is accompanied by improvements in metabolic parameters such as waist circumference and HOMA-IR, indicating a potential benefit for patients with obesity and associated comorbidities
What if I am not home when my food arrives
